Clovis Oncology, Inc. (NASDAQ:CLVS) persists its position slightly strong in context of buying side, while shares price jumped up 27.24% during latest trading session. Clovis Oncology, Inc. (CLVS) reported financial results for quarter ended June 30, 2016, and provided an update on the Company’s clinical development programs and regulatory outlook for the remainder of 2016.
President and CEO of Clovis Oncology, Patrick J. Mahaffy stated that they are pleased to have completed the submission of their NDA for rucaparib in treatment of advanced ovarian cancer in late June.” He continued “We continue to focus on our broader clinical development program for rucaparib, and are actively preparing for a potential U.S. launch of rucaparib.”
Narrow down focus to other ratios, the co has current ratio of 5.50 that indicates if CLVS lies in 1.3% to 3% then it is acceptable for both active and passive investors, but sometimes its varies industry to industry. Generally, it indicates good short-term financial strength. Street is more conscious on this after SunEdison, Inc. case. To make strengthen these views, the active industry firm has Quick Ratio of 5.50, which indicates firm has sufficient short-term assets to cover its immediate liabilities. In addition, the firm has debt to equity ratio of 2.49, sometimes its remain same with long term debt to equity ratio.
Following previous ticker characteristics, Amgen Inc. (NASDAQ:AMGN) also run on active notice, stock price eased up 0.03% after traded at $174.40 in most recent trading session.
AMGN has price to earnings ratio of 17.85 and the price to current year EPS stands at 35.20%. Whereas the traders who further want to see about this, may be interested to see Price to next year’s EPS that would be 9.87%. The earning yield also gives right direction to lure investment, as the co has 2.29% dividend yield. Moving toward ratio analysis, it has current ratio of 4.00 and quick ratio was calculated as 3.70. The debt to equity ratio appeared as 1.10 for seeing its liquidity position.
Taking notice on volatility measures, price volatility of stock was 1.49% for a week and 1.49% for a month. The price volatility’s Average True Range for 14 days was 2.46. On these bases, analysts would recommend this stock as an “Active Revolving Stocks.” The firm attains analyst recommendation of 2.40 out of 1-5 scale with week’s performance of 1.30%. AMGN’s institutional ownership was registered as 81.10%, while insider ownership was 0.20%.